Organon & -Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know

Company Performance - Organon (OGN) closed at $16.26, with a gain of +1.82% from the previous trading session, outperforming the S&P 500's loss of 1.46% [1] - Over the past month, Organon shares increased by 6.04%, surpassing the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% [1] Upcoming Earnings - Organon's earnings report is scheduled for February 13, 2025, with projected earnings per share (EPS) of$ 0.87, reflecting a 1.14% decrease from the same quarter last year [2] - The consensus estimate for revenue is $1.57 billion, down 1.87% from the prior-year quarter [2] Analyst Estimates - Recent changes to analyst estimates for Organon are important as they reflect near-term business trends, with positive revisions indicating a favorable outlook on the company's health and profitability [3] - The Zacks Consensus EPS estimate has shifted 0.97% downward over the past month, resulting in a Zacks Rank of 4 (Sell) for Organon [5] Valuation Metrics - Organon is currently trading with a Forward P/E ratio of 3.93, significantly lower than the industry average of 17.43 [6] - The company has a PEG ratio of 0.83, compared to the Medical Services industry average PEG ratio of 1.56 [6] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 159, placing it in the bottom 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]